Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

被引：0
|
作者：
Eliazar Sabater
Armando López-Guillermo
Antonio Rueda
Antonio Salar
Itziar Oyagüez
Juan Manuel Collar
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia,Haematology Department
[2] Hospital Clinic,Oncology Department
[3] Hospital Costa del Sol,Haematology Department
[4] Hospital del Mar,Medical Department
[5] Mundipharma Pharmaceuticals,undefined
来源：
Applied Health Economics and Health Policy | 2016年 / 14卷
关键词：
Follicular Lymphoma; Bendamustine; Bayesian Information Criterion; Progression State; Spanish National Health System;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 477
页数：12
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [2] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [3] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [4] Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma
    Hornberger, J.
    Reyes, C.
    Verhulst, E.
    Lubeck, D.
    Valente, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [6] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [7] FIRST LINE TREATMENT WITH BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Buenasmananas Cervantes, D.
    Calle Primo, C.
    Nebro Luque, M. dM
    Hernandez Ruiz, B.
    HAEMATOLOGICA, 2015, 100 : 266 - 266
  • [8] Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Ta, Jamie T.
    Seetasith, Arpamas
    Wang, Rongrong
    Lai, Dominic
    Shapouri, Sheila
    BLOOD, 2021, 138
  • [9] EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK
    Rafia, R.
    Papaioannou, D.
    Stevenson, M.
    Rathbone, J.
    Woods, H. B.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A445
  • [10] COST-EFFECTIVENESS OF DUVELISIB VERSUS THE BENDAMUSTINE PLUS RITUXIMAB REGIMEN FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS IN CHINA
    Chen, L.
    Tan, B.
    Gao, X.
    Zhou, K.
    Zhao, J.
    Xuan, J.
    VALUE IN HEALTH, 2023, 26 (12) : S181 - S182
12345